During the past decade, Azienda Unità Sanitaria Locale di Reggio Emilia/IRCCS conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Azienda Unità Sanitaria Locale di Reggio Emilia/IRCCS" #1 sponsor was "Amgen" with 2 trials, followed by "Hoffmann-La Roche" with 2 trials sponsored, "Arcispedale Santa Maria Nuova-IRCCS" with 1 trials sponsored, "Mario Negri Institute for Pharmacological Research" with 1 trials sponsored and "QED Therapeutics, Inc." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Unità Sanitaria Locale di Reggio Emilia/IRCCS" #1 collaborator was "Helsinn Healthcare SA" with 1 trials as a collaborator and "University of Modena and Reggio Emilia" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Azienda Unità Sanitaria Locale di Reggio Emilia/IRCCS" are "Blincyto Use in Routine Clinical Practice" (1 trials), "Health Behavior" (1 trials), "Lifestyle, Sedentary" (1 trials), "Locally Advanced or Metastatic Breast Cancer" (1 trials) and "Metastatic Breast Cancer" (1 trials). Many other conditions were trialed in "Azienda Unità Sanitaria Locale di Reggio Emilia/IRCCS" in a lesser frequency.

Most popular intervention types in "Azienda Unità Sanitaria Locale di Reggio Emilia/IRCCS" are "Drug" (4 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Acetylcarnitine" (1 trials), "Atezolizumab" (1 trials), "Docetaxel" (1 trials) and "Giredestrant" (1 trials). Other intervention names were less common.

The vast majority of trials in "Azienda Unità Sanitaria Locale di Reggio Emilia/IRCCS" are 7 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Azienda Unità Sanitaria Locale di Reggio Emilia/IRCCS". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Azienda Unità Sanitaria Locale di Reggio Emilia/IRCCS, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Azienda Unità Sanitaria Locale di Reggio Emilia/IRCCS, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".